Literature DB >> 16026120

Atherosclerosis and innate immune signaling.

Marc A Laberge1, Kathryn J Moore, Mason W Freeman.   

Abstract

Atherosclerosis, the leading cause of death in developed countries, is characterized by chronic inflammation in the artery wall. It has been appreciated for decades that this disease is linked to hypercholesterolemia and the accumulation of macrophages in the artery wall, yet the exact mechanisms underlying this inflammatory process remain unclear. The role of innate and adaptive immune responses in the pathogenesis of atherosclerosis has been an area of intense study. It now appears that activation of innate immune signaling pathways designed to protect us from microbes may be responsible for initiating and feeding the chronic inflammatory cascade that characterizes this disease. In this review, we discuss the recent identification of Toll-like receptors and their downstream signaling pathways as critical contributors to atherosclerosis. Unraveling the contribution of individual Toll-like receptors and identifying the ligands that activate these pathways will be a central focus of atherosclerosis research in the next few years. The involvement of these pathways in atherogenesis will not only open up new avenues of investigation, but it also provides new targets for therapeutic manipulation that could ameliorate the atherosclerotic inflammatory response directly.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16026120     DOI: 10.1080/07853890510007304

Source DB:  PubMed          Journal:  Ann Med        ISSN: 0785-3890            Impact factor:   4.709


  13 in total

1.  Fungal pathogen recognition by scavenger receptors in nematodes and mammals.

Authors:  Terry K Means
Journal:  Virulence       Date:  2010 Jan-Feb       Impact factor: 5.882

Review 2.  Role of Toll-like receptors in infection and immunity: clinical implications.

Authors:  Patricia Cristofaro; Steven M Opal
Journal:  Drugs       Date:  2006       Impact factor: 9.546

3.  Targeting Innate Immunity for CV Benefit.

Authors:  Kathryn J Moore; Mason W Freeman
Journal:  Drug Discov Today Ther Strateg       Date:  2008

Review 4.  Thematic review series: proteomics. Proteomic analysis of lipid-protein complexes.

Authors:  Tomas Vaisar
Journal:  J Lipid Res       Date:  2009-02-19       Impact factor: 5.922

Review 5.  Integrating computational and biochemical studies to explore mechanisms in NF-{kappa}B signaling.

Authors:  Jeffrey D Kearns; Alexander Hoffmann
Journal:  J Biol Chem       Date:  2008-10-20       Impact factor: 5.157

6.  HDL in humans with cardiovascular disease exhibits a proteomic signature.

Authors:  Tomás Vaisar; Philip Mayer; Erik Nilsson; Xue-Qiao Zhao; Robert Knopp; Bryan J Prazen
Journal:  Clin Chim Acta       Date:  2010-03-20       Impact factor: 3.786

7.  Hsa-miRNA-23a-3p promotes atherogenesis in a novel mouse model of atherosclerosis.

Authors:  Jiayan Guo; Hanbing Mei; Zhen Sheng; Qingyuan Meng; Murielle M Véniant; Hong Yin
Journal:  J Lipid Res       Date:  2020-10-02       Impact factor: 5.922

Review 8.  Therapeutic targeting of NOD1 receptors.

Authors:  L Moreno; T Gatheral
Journal:  Br J Pharmacol       Date:  2013-10       Impact factor: 8.739

9.  Plant and animal pathogen recognition receptors signal through non-RD kinases.

Authors:  Christopher Dardick; Pamela Ronald
Journal:  PLoS Pathog       Date:  2006-01-20       Impact factor: 6.823

Review 10.  Role of Nucleotide-binding and Oligomerization Domain 2 Protein (NOD2) in the Development of Atherosclerosis.

Authors:  Ha-Jeong Kim
Journal:  Korean J Physiol Pharmacol       Date:  2015-10-16       Impact factor: 2.016

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.